SPRB — Spruce Biosciences Balance Sheet
0.000.00%
- $89.27m
- $79.14m
- $4.91m
Annual balance sheet for Spruce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 157 | 89 | 79.1 | 96.3 | 38.8 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 160 | 91.9 | 83.6 | 102 | 44.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.79 | 1.65 | 1.4 | 1.18 | 0.934 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 163 | 126 | 85.6 | 104 | 45.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.76 | 8.87 | 12.4 | 24.5 | 15.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 13.5 | 15.1 | 17.2 | 27.4 | 16.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 149 | 111 | 68.5 | 76.5 | 28.8 |
| Total Liabilities & Shareholders' Equity | 163 | 126 | 85.6 | 104 | 45.2 |
| Total Common Shares Outstanding |